Brett Hall (@Biomarker) header
Brett Hall (@Biomarker) profile picture

Entrepreneur

San Diego, CA
Joined November 2012
Photo by Brett Hall (@Biomarker)
Great to see: Tissue Agnostic Drug Development in Oncology fda.gov/regulatory-informati…
$IMRX CEO Ben Zeskind and CSO Brett Hall will be participating in a fireside chat at the @MorganStanley 20th Annual Global Healthcare Conference this Wednesday Sept 14 at 2:05PM ET. For more info click here: buff.ly/3Csnms5
2
3
We are advancing pipelines of drug programs focused on treating aspects of disease that have eluded conventional drug discovery in #oncology, #neuroscience, and #immunoOncology. For a more in-depth look at our progress, click here: https://teapawt.net/t.co/qFLJufefhY
1
4
Excellent summary to better understand the goal of the current global shutdowns: What This Chart Actually Means for COVID-19 youtu.be/fgBla7RepXU via @YouTube
1
#DYK: The life-threatening condition known as #cachexia occurs in up to 80% of all #cancers? Cachexia is characterized by muscle mass loss that is often accompanied by weight loss. Learn more about cachexia here: https://teapawt.net/t.co/sS0WaxqyMX
2
4
FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic - CANCER RESEARCH Catalyst blog.aacr.org/fda-approves-n…
World-class drug discovery using state-of-the-art computational and A.I. platforms.
Replying to @Evotec
@EvotecAG today announced that it has entered into a research collaboration with @Immuneering Corporation to discover novel small molecules for rare hereditary metabolic diseases | press release evotec.com/en/invest/news--a…
1
Another great publication from @Immuneering team members and collaborators! #huntingtonsdisease @BioMedCentral #openaccess teapawt.net/Becky_Kusko/status/998…
Like a paper which summarizes key findings in a cartoon figure? Check out Fig. 8 in my latest #openaccess #huntington publication together with @Immuneering colleagues and other great collaborators in @BioMedCentral https://teapawt.net/t.co/c9xuAJl6rO
2
2
We are excited to announce our joint research collaboration with @TheDDFund, to identify novel drug targets and drug candidates for Alzheimer's disease. #Alzheimers #DrugDiscovery https://teapawt.net/t.co/JQPQXRlcrt immuneering.com
Overall likelihood of approval from Ph 1 for all drug candidates was 9.6%. However, oncology was only 5.1% lnkd.in/g32vjDf lnkd.in/grWbxKb
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party bloodjournal.org/content/131…
Asellus Therapeutics Offers an Immune Oncology Drug Development Risk-Share Business Opportunity linkedin.com/pulse/asellus-t…
Excellent review on "Immune Metabolism", an emerging frontier for new immune oncology drugs: cell.com/cell/abstract/S0092…